To assess the effectiveness and safety of once-daily LABA/ICS in a combined inhaler versus once/twice-daily LABA for the treatment of COPD.
This is a protocol.
Once-daily LABA/ICS combined inhalers versus inhaled long-acting beta2-agonists for people with chronic obstructive pulmonary disease (COPD)
You may also be interested in:
- Is once-daily ICS/LABA combined in one inhaler more beneficial than inhaled LAMA for treatment of people with COPD?
- Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for COPD
- Combination therapy of inhaled steroids and long-acting beta2-agonists compared to inhaled steroids alone for people with COPD
- Are tiotropium plus combination inhalers better than tiotropium or combination inhalers alone for the treatment of COPD?
- Combined inhalers compared to tiotropium inhalers for the treatment of chronic obstructive pulmonary disease